Blood Cancer

Latest News

Breyzani Approved For CLL/SLL and FDA Advisory Committee Votes in Favor of Abecma for MM
Breyzani Approved For CLL/SLL and FDA Advisory Committee Votes in Favor of Abecma for MM

March 21st 2024

Last week, BMS announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has voted in favor of BMS’s and 2seventy bio's Abecma (idecabtagene vicleucel) for patients with relapsed or refractory multiple myeloma in earlier lines of therapy.

LASZLO-stock-adobe.com
FDA Approves Iclusig for New Patients with Aggressive Leukemia

March 19th 2024

Pfizer Reports Promising Results in Phase 3 Trial of Adcetris Regimen for Relapsed/​Refractory Diffuse Large B-cell Lymphoma
Pfizer Reports Promising Results in Phase 3 Trial of Adcetris Regimen for Relapsed/​Refractory Diffuse Large B-cell Lymphoma

March 19th 2024

Promising Results for Crenolanib with Intensive Chemotherapy in Adults with FLT3-Mutated AML
Promising Results for Crenolanib with Intensive Chemotherapy in Adults with FLT3-Mutated AML

February 26th 2024

© 2024 MJH Life Sciences

All rights reserved.